806 / 1851
Trial
N of
patients
IMRT Regimen
Toxicity Efficacy
Feliu et al,
ASCO 2014
GEMCAD 09-02
58
No
45 Gy
+ boost of
10-15 Gy
5-FU/MMC
+RT +
panitumumab
High
33/36
(92%)
G3/4 AE
At 24
weeks 55%
had CR
Tri
als with Panitumumab/RT in anal cancer